Immunic Showcases Vidofludimus Calcium Research at ACTRIMS 2025 Forum

Immunic Presents Insights on Vidofludimus Calcium at ACTRIMS 2025

Immunic, Inc., a biotechnology firm listed on Nasdaq under the ticker IMUX, made significant strides by presenting its latest findings on Vidofludimus Calcium (IMU-838) at the ACTRIMS Forum 2025, which is being held from February 27 to March 1 in West Palm Beach, Florida. This forum, known for bringing together experts in multiple sclerosis (MS) research, provided an ideal platform for Immunic to share its advancements in developing promising treatments for chronic inflammatory and autoimmune diseases.

Significance of Vidofludimus Calcium in MS Treatment

Vidofludimus Calcium is positioned as a groundbreaking oral therapy that has showcased potential in addressing progressive forms of multiple sclerosis. The drug is distinctive as it functions as a nuclear receptor-related 1 (Nurr1) activator, which is vital in combating neuronal loss and injury. In a statement, Daniel Vitt, Ph.D., the CEO of Immunic, emphasized that having two poster presentations at ACTRIMS highlights the importance of their research.

During the presentations, information was shared that highlighted baseline characteristics of patients involved in Immunic's Phase 2 CALLIPER trial for progressive multiple sclerosis. This analysis included comparisons to baseline data from four prominent trials, shedding light on how various factors could impact trial outcomes along with their upcoming data readout expected in April. Vitt noted that understanding how Vidofludimus Calcium affects confirmed disability worsening over 24 weeks could reveal insights into its influence on central nervous system pathology.

Data Presentation Details

1. Poster Title: Baseline Characteristics Across Major Clinical Trials in Progressive Multiple Sclerosis
- Presenting Author: Robert J. Fox, M.D., Staff Neurologist, Cleveland Clinic
- Abstract Number: 452
- Poster Number: P102
- Session Date: February 27, 2025
- Session Time: 6:00 PM – 7:30 PM ET

2. Poster Title: Vidofludimus Calcium Shows a Potential Neuroprotective Function in Multiple Sclerosis through its Activity on Nurr1 in Preclinical Models
- Presenting Author: Evelyn Peelen, Ph.D., Head of Research, Immunic
- Abstract Number: 427
- Poster Number: P317
- Session Date: February 28, 2025
- Session Time: 6:00 PM – 7:30 PM ET

Both presentations are expected to be crucial in demonstrating how Vidofludimus Calcium may reduce neuronal damage by modulating microglial activity, a critical component of neuroinflammation and neuroprotection. Continued research reveals that its capability to activate Nurr1 is central to its neuroprotective function.

Overview of Vidofludimus Calcium

Vidofludimus Calcium is classified as a small molecule investigational drug and is under extensive clinical evaluation as an innovative oral treatment for multiple sclerosis and other chronic conditions. Its selective immune modulator role positions it to activate the neuroprotective transcription factor Nurr1 effectively. Furthermore, it acts as a highly selective inhibitor of dihydroorotate dehydrogenase (DHODH), crucial for managing immune responses, particularly in hyperactive T and B cells, while preserving normal immune function necessary for fighting infections. Thus far, Vidofludimus Calcium has demonstrated a solid pharmacokinetic profile and safety in over 1,800 individuals involved in its trials.

Conclusion

Immunic's participation at the ACTRIMS Forum 2025 symbolizes a pivotal advancement in the fight against multiple sclerosis, showcasing their commitment to developing innovative treatment options for afflicted patients. As the company gears up for further analyses in their ongoing clinical trials, anticipation builds around the potential that Vidofludimus Calcium holds for transforming treatment paradigms in neurodegenerative diseases.

For further information about Immunic and their ongoing clinical programs, interested parties can visit their official website.